REAX vs. NVO
REAX (Real Brokerage Inc) and NVO (Novo Nordisk A/S) are both stocks. REAX operates in Real Estate - Services (Real Estate), while NVO operates in Drug Manufacturers - General (Healthcare). Over the past 5 years, REAX returned -24.39%/yr vs 4.73%/yr for NVO. At a 0.13 correlation, their price movements are largely independent.
Performance
REAX vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, REAX achieves a -43.29% return, which is significantly lower than NVO's 0.24% return.
REAX
- 1D
- 0.98%
- 1M
- 27.78%
- 6M
- -51.52%
- YTD
- -43.29%
- 1Y
- -48.76%
- 3Y*
- 5.76%
- 5Y*
- -24.39%
- 10Y*
- —
NVO
- 1D
- -0.40%
- 1M
- 12.31%
- 6M
- -14.80%
- YTD
- 0.24%
- 1Y
- -25.17%
- 3Y*
- -12.72%
- 5Y*
- 4.73%
- 10Y*
- 8.21%
REAX vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
REAX Real Brokerage Inc | -43.29% | -20.65% | 187.50% | 52.38% | -71.54% | -59.05% |
NVO Novo Nordisk A/S | 0.24% | -39.22% | -15.93% | 54.84% | 22.66% | 33.38% |
Correlation
The correlation between REAX and NVO is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Jun 15, 2021 | 0.13 |
Fundamentals
REAX:
$444.24M
NVO:
$218.99B
REAX:
-$0.03
NVO:
DKK 27.42
REAX:
0.22
NVO:
4.39
REAX:
7.05
NVO:
7.08
REAX:
$2.08B
NVO:
DKK 327.80B
REAX:
$173.33M
NVO:
DKK 268.30B
REAX:
-$4.17M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
REAX vs. NVO — Risk / Return Rank
REAX
NVO
REAX vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Real Brokerage Inc (REAX) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| REAX | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.34 | ||
| Sortino ratioReturn per unit of downside risk | -0.72 | ||
| Omega ratioGain probability vs. loss probability | 0.87 | 0.94 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | -0.69 | -0.51 | -0.18 |
| Martin ratioReturn relative to average drawdown | -1.15 | -0.80 | -0.35 |
Loading charts...
Drawdowns
REAX vs. NVO - Drawdown Comparison
The maximum REAX drawdown since its inception was -89.60%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for REAX and NVO.
Loading charts...
Drawdown Indicators
| REAX | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.60% | -74.70% | -14.90% |
Max Drawdown (1Y)Largest decline over 1 year | -70.45% | -49.17% | -21.28% |
Max Drawdown (3Y)Largest decline over 3 years | -76.13% | -74.70% | -1.43% |
Max Drawdown (5Y)Largest decline over 5 years | -87.60% | -74.70% | -12.90% |
Max Drawdown (10Y)Largest decline over 10 years | — | -74.70% | — |
Current DrawdownCurrent decline from peak | -79.30% | -64.19% | -15.11% |
Average DrawdownAverage peak-to-trough decline | -69.52% | -17.87% | -51.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 42.29% | 31.54% | +10.75% |
Volatility
REAX vs. NVO - Volatility Comparison
Real Brokerage Inc (REAX) has a higher volatility of 17.47% compared to Novo Nordisk A/S (NVO) at 8.73%. This indicates that REAX's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| REAX | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.47% | 8.73% | +8.74% |
Volatility (6M)Calculated over the trailing 6-month period | 49.59% | 37.44% | +12.15% |
Volatility (1Y)Calculated over the trailing 1-year period | 59.28% | 51.74% | +7.54% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 71.47% | 38.53% | +32.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 71.17% | 32.60% | +38.57% |
Dividends
REAX vs. NVO - Dividend Comparison
REAX has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.66%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 3.66% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
REAX Real Brokerage Inc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
REAX vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Real Brokerage Inc and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
REAX vs. NVO - Profitability Comparison
REAX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Real Brokerage Inc reported a gross profit of 41.58M and revenue of 465.55M. Therefore, the gross margin over that period was 8.9%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
REAX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Real Brokerage Inc reported an operating income of -3.13M and revenue of 465.55M, resulting in an operating margin of -0.7%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
REAX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Real Brokerage Inc reported a net income of -3.42M and revenue of 465.55M, resulting in a net margin of -0.7%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
Frequently Asked Questions
REAX and NVO have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
REAX has higher volatility (17.47%) compared to NVO (8.73%). In terms of maximum drawdown, REAX dropped -89.60% vs NVO's -74.70%.
NVO currently has the higher Sharpe Ratio (-0.49 vs -0.83), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for REAX and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer